CO5640114A2 - 4-(2,4-dicloro-5-metoxifenil)amino -6-alcoxi-3-quinolincarbonitrilos para el tratamiento de lesiones isquemicas - Google Patents

4-(2,4-dicloro-5-metoxifenil)amino -6-alcoxi-3-quinolincarbonitrilos para el tratamiento de lesiones isquemicas

Info

Publication number
CO5640114A2
CO5640114A2 CO05081472A CO05081472A CO5640114A2 CO 5640114 A2 CO5640114 A2 CO 5640114A2 CO 05081472 A CO05081472 A CO 05081472A CO 05081472 A CO05081472 A CO 05081472A CO 5640114 A2 CO5640114 A2 CO 5640114A2
Authority
CO
Colombia
Prior art keywords
formula
chinolincarbonitrils
metoxifenil
dicloro
alcoxi
Prior art date
Application number
CO05081472A
Other languages
English (en)
Spanish (es)
Inventor
Diane Harris Boschelli
Margaret Maria Zaleska
Frank Charles Boschelli
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32927510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5640114(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CO5640114A2 publication Critical patent/CO5640114A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47064-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CO05081472A 2003-02-21 2005-08-17 4-(2,4-dicloro-5-metoxifenil)amino -6-alcoxi-3-quinolincarbonitrilos para el tratamiento de lesiones isquemicas CO5640114A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44931603P 2003-02-21 2003-02-21

Publications (1)

Publication Number Publication Date
CO5640114A2 true CO5640114A2 (es) 2006-05-31

Family

ID=32927510

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05081472A CO5640114A2 (es) 2003-02-21 2005-08-17 4-(2,4-dicloro-5-metoxifenil)amino -6-alcoxi-3-quinolincarbonitrilos para el tratamiento de lesiones isquemicas

Country Status (19)

Country Link
US (1) US20040229880A1 (enExample)
EP (1) EP1594502A1 (enExample)
JP (1) JP2006522023A (enExample)
KR (1) KR20050102133A (enExample)
CN (1) CN1750824A (enExample)
AR (1) AR043253A1 (enExample)
AU (1) AU2004216235A1 (enExample)
BR (1) BRPI0407441A (enExample)
CA (1) CA2516418A1 (enExample)
CO (1) CO5640114A2 (enExample)
CR (1) CR7931A (enExample)
EC (1) ECSP055972A (enExample)
MX (1) MXPA05008706A (enExample)
NO (1) NO20054070L (enExample)
RU (1) RU2005129333A (enExample)
TW (1) TW200423938A (enExample)
UA (1) UA80472C2 (enExample)
WO (1) WO2004075898A1 (enExample)
ZA (1) ZA200506621B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG146681A1 (en) * 2003-11-06 2008-10-30 Wyeth Corp 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
RU2007111704A (ru) * 2004-10-22 2008-11-27 Вайет (Us) 4[(2,4-дихлоро-5-метоксифенил)амино]-6-алкокси-7-этинил-3-хинолинкарбонитрилы для лечения ишемического поражения
MX2008000384A (es) * 2005-07-01 2008-03-07 Wyeth Corp Formas cristalinas de 4-[(2,4-dicloro-5-metoxifenil)amino]-6-metox i-7-[3-(4-metil-1-piperazinil)propoxi]-3-quinolinocarbonitrilo y metodos para su preparacion.
MX342879B (es) 2010-07-30 2016-10-14 Oncotherapy Science Inc * Derivados de quinolina e inhibidores de cinasa de cremallera de leucina embrionica materna que los contienen.
CN103772392A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
IN2014CH00840A (enExample) 2014-02-20 2015-09-18 Apotex Inc
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ros1突變癌細胞之分子
US20160256457A1 (en) * 2014-06-10 2016-09-08 Beth Israel Deaconess Medical Center, Inc. Methods for treating or preventing acute vascular leak
AU2015355220B2 (en) 2014-12-02 2020-02-27 Ignyta, Inc. Combinations for the treatment of neuroblastoma
WO2017029584A1 (en) * 2015-08-19 2017-02-23 Sun Pharmaceutical Industries Limited Amorphous form of bosutinib
KR20180096621A (ko) 2015-12-18 2018-08-29 이그니타, 인코포레이티드 암의 치료용 조합물
CN107814769B (zh) * 2016-09-14 2021-05-07 正大天晴药业集团股份有限公司 一种博舒替尼的纯化方法
WO2019018570A1 (en) 2017-07-19 2019-01-24 Ignyta, Inc. PHARMACEUTICAL COMPOSITIONS CONTAINING ENTRECTINIB
JP7311498B2 (ja) 2017-10-17 2023-07-19 イグナイタ インコーポレイテッド 薬学的組成物および剤形
CN111646940B (zh) * 2019-03-04 2024-01-30 鲁南制药集团股份有限公司 一种博舒替尼中间体的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6521618B2 (en) * 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US20060167021A1 (en) * 2002-10-04 2006-07-27 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Inhibition of src for treatment of reperfusion injury related to revascularization

Also Published As

Publication number Publication date
WO2004075898A1 (en) 2004-09-10
TW200423938A (en) 2004-11-16
US20040229880A1 (en) 2004-11-18
NO20054070D0 (no) 2005-09-01
MXPA05008706A (es) 2005-10-05
KR20050102133A (ko) 2005-10-25
RU2005129333A (ru) 2006-01-27
CA2516418A1 (en) 2004-09-10
AR043253A1 (es) 2005-07-20
JP2006522023A (ja) 2006-09-28
ZA200506621B (en) 2008-02-27
NO20054070L (no) 2005-11-14
ECSP055972A (es) 2006-01-16
BRPI0407441A (pt) 2006-01-31
AU2004216235A1 (en) 2004-09-10
UA80472C2 (en) 2007-09-25
CR7931A (es) 2006-02-07
CN1750824A (zh) 2006-03-22
EP1594502A1 (en) 2005-11-16

Similar Documents

Publication Publication Date Title
CO5640114A2 (es) 4-(2,4-dicloro-5-metoxifenil)amino -6-alcoxi-3-quinolincarbonitrilos para el tratamiento de lesiones isquemicas
UY27918A1 (es) Derivados de benzodioxol
AR018705A1 (es) Procedimientos e intermedios para preparar compuestos anticancerosos.
CY1118572T1 (el) Παραγωγο κυκλοαλκανιου
CY1107008T1 (el) Παραγωγο βενζιμιδαζολης και χρηση ως ανταγωνιστου υποδοχεα aii
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
PA8593001A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
JO2282B1 (en) Oxazole derivatives
AR060749A1 (es) Uso de bifenilamidas de acido arilcarboxilico para el tratamiento de semillas
DK1585739T3 (da) Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer
PA8509301A1 (es) Inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en enfermedades inflamatorias, autoinmunes y respiratorias
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
AR077478A2 (es) Derivados de oxindol sustituido medicamentos que los comprenden y uso de los mismos
UY28695A1 (es) Derivados de difenilazetidona
BRPI0412999A (pt) 2-aminotetralina substituìda para tratamento de depressão
AR029821A1 (es) Decahidro-isoquinolinas, un proceso para su preparacion, composiciones farmaceuticas que las comprenden y el uso de las mismas para la fabricacion de un medicamento
RU2005105564A (ru) Производные бензимидазола и их применение в качестве пролекарств ингибиторов протонного насоса
UY27338A1 (es) Nuevos derivados de ácido sulfónico
AR050518A1 (es) Proceso de amonolisis para la preparacion de intermedarios para inhibidores de dpp iv
UY27803A1 (es) Derivados de benzoxazina y usos de los mismos.
PA8581201A1 (es) Nuevos derivados de tiazol
MXPA04001277A (es) Imidazopiridinas triciclicas.
UY27770A1 (es) Imidazolinilmetil aralquilsulfonamidas
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
AR036735A1 (es) Derivados de 5-metoxi-8-aril-[1,2,4]triazolo[1,5-a]piridina

Legal Events

Date Code Title Description
FC Application refused